1.
Bioorg Med Chem Lett
; 22(1): 689-95, 2012 Jan 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22079756
RESUMO
Libraries of dibasic compounds designed around the molecular scaffold of the DA(2)/ß(2) dual agonist sibenadet (Viozan™) have yielded a number of promising starting points that have been further optimised into novel potent and selective target molecules with required pharmacokinetic properties. From a shortlist, 31 was discovered as a novel, high potency, and highly efficacious ß(2)-agonist with high selectivity and a duration of action commensurable with once daily dosing.